PellePharm
2012
FOUNDED
PRIVATE
STATUS
Corporate
LATEST DEAL TYPE
$70M
LATEST DEAL AMOUNT
7
INVESTORS
Description
Developer of skin cancer therapeutics intended to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
- 101 Mission Street
- Suite 2050
- San Francisco, CA
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore PellePharm’s full profile, request a free trial.
PellePharm Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Corporate | 20-Nov-2018 | $70M | 00000 | Completed | Clinical Trials - Phase 2 | |
| 5. Later Stage VC (Series C) | 18-Jun-2018 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Debt - General | 29-Mar-2018 | 00.00 | 000.00 | Completed | ||
| 3. Early Stage VC (Series B2) | 31-Jul-2017 | 0000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 2. Early Stage VC (Series B) | 23-Jul-2015 | $4.55M | $7.67M | 000.00 | Completed | Startup |
| 1. Early Stage VC (Series A) | 11-May-2015 | $3.12M | $3.12M | 00.00 | Completed | Startup |
PellePharm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series A | 3,712,649 | $0.000100 | $0.84 | $0.84 | 1x | $0.84 | 12.07% |
PellePharm Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| LEO Pharma | Corporation | Minority | 000 0000 | 000000 0 | ||
| Aisling Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| BridgeBio | Corporation | Minority | 000 0000 | 000000 0 | ||
| The Atlanta Trust | Other | Minority | 000 0000 | 000000 0 |
PellePharm Executive Team (5)
1 Former Executive
You’re viewing 4 of 5 executives. Get the full list »PellePharm Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Eric Aguiar MD | Aisling Capital | Board Observer | 000 0000 | |
| Ervin Epstein MD | PellePharm | Co-Founder, President, Chief Medical Officer & Board Member | 000 0000 | |
| Frank McCormick Ph.D | Self | Board Member | 000 0000 | |
| Jean Tang MD | PellePharm | Board Member & Co-Founder | 000 0000 | |
| Katrin Andreasson | PellePharm | Board Member | 000 0000 |